Eplerenone: A selective aldosterone blocker

Cardiovascular Drug Reviews

Volumn 21, Issue 3, 2003, Pages 169-184

  Stier Jr , Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Aldosterone; Cardiovascular disease; Eplerenone; Heart failure; Hypertension; Selective aldosterone blocker

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; ERYTHROMYCIN; FLUCONAZOLE; KETOCONAZOLE; LOSARTAN; PROGESTERONE RECEPTOR; SAQUINAVIR; SELECTIVE ALDOSTERONE ANTAGONIST; SPIRONOLACTONE; UNCLASSIFIED DRUG; VERAPAMIL;

ADD ON THERAPY; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HORMONE INHIBITION; HUMAN; HYPERCOAGULABILITY; HYPERKALEMIA; HYPERTENSION; INFLAMMATION; KIDNEY INJURY; MONOTHERAPY; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; STROKE; VASCULAR ENDOTHELIUM; VASCULAR FIBROSIS; VASCULAR NECROSIS; VASCULITIS;

EID: 0141919797     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2003.tb00114.x     Document Type: Review

References (80)

1. Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats: Kidney Int 2003;63:1791-1800.
2. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 2000;25:299-306.
3. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.
4. Burgess E, Lacourciere Y, Puopolo A, Camplin J, Roniker B, Krause E and the eplerenone 025 Investigators. The selective aldosterone blocker eplerenone is safe and efficacious for the long-term treatment of mild-to-moderate hypertension. Am J Hypertens 2002;15:57A.
5. Coleman CI, Reddy P, Song JC, White CM. Eplerenone, the first selective aldosterone receptor antagonist for the treatment of hypertension. Formulary 2002;37:514-524.
6. Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, Zhang L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002;30:1344-1351.
7. Cook CS, Zhang L, Ames GB, Fischer J, Zhang J, Levin S. Single-and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. Xenobiotica 2003;33:305-321.
8. Cook CS, Zhang L, Fischer JS. Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. Pharm Res 2000;17:1426-1431.
9. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-656.
10. Delyani JA. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int 2000;57:1408-1411.
11. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;50:H647-H654.
12. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: A selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001;19:185-200.
13. Drayer JI, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 1983;5:108-113.
14. Epstein M, Buckalew V Jr, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15:24A.
15. Fiebeler A, Schmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin 11-induced cardiac injury. Hypertension 2001;37:787-793.
16. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-1155.
17. Funder JW. Eplerenone, a new mineralocorticoid antagonist: In vitro and in vivo studies. Curr Opin Endocrinol Diabetes 2000;7:138-142.
18. Gibbs CR, Beevers DG, Lip GYH. The management of hypertensive disease in black patients. Quart J Med 1999;92:187-192.
19. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-1057.
20. Kannel WB. Risk stratification in hypertension: New insights from the Framingham study. Am J Hypertens 2000;13:3S-10S.
21. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-123.
22. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats. Effects of eplerenone. Circulation 2002;106:2848-2853.
23. Leenen FHH, Myers MG, Joyner CD, Toal CB. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS vs. felodipine-ER vs. enalapril. Can J Cardiol 2002;18:1285-1293.
24. Menard J,. Bittman R, Gatlin M. Eplerenone dose-response relationship for aldosterone blockade. Am J Hypertens 2003;16:166A.
25. Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The insulin resistance atherosclerosis study (IRAS). Stroke 1997;28:1710-1716.
26. Inspra™ [package insert]: Chicago, IL: GD Searle LLC (a subsidiary of Pharmacia Corporation); 2002.
27. Pitt B, Reichek N, Metscher R, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. Am J Hypertens 2002;15:23A-24A.
28. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
29. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
30. Quaschning T, Ruschitzka F, Shaw S, Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001;37:801-805.
31. Rabasseda X, Silvestre J, Castaner J. Eplerenone. Drugs Future 1999;24(5):488-501.
32. Rajagopalan S, Duquaine D, King S, Pitt P, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-2216.
33. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
34. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats. Hypertension 1998;32:598A.
35. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999;33:232-237.
36. Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143:4828-4836.
37. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002:283:H1802-H1810.
38. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-314.
39. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878.
40. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62(5):723-731.
41. Ruilope LM, Weber M, Garcia-Puig J, et al. Antihypertensive and end-organ protective effects of eplerenone and enalapril in patients with essential hypertension. Japanese Society of Hypertension 25th Annual Meeting; Tokyo, Japan (October 10-12, 2002)A.
42. Schafer A, Fraccarollo D, Hildemann SK, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: Effect on endothelial function. Cardiovasc Res 2003;58:655-662.
43. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000;85:1199-1206.
44. Sica DA. Eplerenone. and serum potassium change - relationship to renal function. Am J Hypertens 2003; 16:100A.
45. Sica DA. Aldosterone receptor blockade: A therapy resurrected. Heart Dis 2003;5:85-88.
46. Sica DA. Eplerenone: A new aldosterone receptor antagonist - are the FDAs restrictions appropriate? J Clin Hypertens (Greenwich) 2002;5:441-445.
47. Silvestre JS, Heymes C, Delcayre C, et al. Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin 11 receptor blockade and role in cardiac fibrosis. Circulation 1999;99: 2694-2701.
48. Spertus JA, Tooley J, Jones P, et al. Expanding the outcomes in clinical trials of heart failure: The quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J 2002;143:636-642.
49. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin 11 suppression. J Endocrinol 1981;91:457-465.
50. Stier CT Jr, Chander PN, Mullen D, Lesnick G, Rocha R. Eplerenone lessens blood pressure elevation in non-salt-loaded stroke-prone hypertensive rats. Am J Hypertens 1999;12(4):113A.
51. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002;10:97-106.
52. Stier CT Jr, Chander PN, Zuckerman A, Rocha R. Non-epithelial effects of aldosterone. Curr Opin Endocrinol Diabetes 1998;5(3):211-216.
53. Stier CT Jr, Chander PN, Zuckerman A, Rocha R. Vascular protective effect of a selective aldosterone receptor antagonist in stroke-prone hypertensive rats. 25th Annual International Aldosterone Conference San Diego, June 10-11, 1999:22.
54. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
55. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone- induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol 2002;161:1773-1781.
56. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-2972.
57. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
58. Tolbert DS, Karim A, Cook C, et al. SC-66110 (Eplerenone): A selective antialdosterone antagonist. Disposition kinetics in man and identification of its major CYP450 isoenzymes in its biotransformation. AAPS Pharm Sci 1998;Suppl 1:1155A.
59. Tolbert DS, Reid SE, Roniker B. Safety, tolerability, and pharmacokinetics of eplerenone, a selective aldosterone blocker. Presented as a poster at the 2002 Annual American College of Clinical Pharmacology; Albuquerque NM (October 20-23, 2002)A.
60. Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone in special populations. Pharmaco 2002;22:1332A.
61. Tolbert DS, Reid SE, Roniker B. Safety, tolerability and pharmacokinetics of eplerenone, a selective aldosterone blocker. Pharmaco 2002;22:1331A.
62. Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone coadministered with other medications. Pharmaco 2002;22,1331 A.
63. Van Mieghem W, von Behren V, Balazovjeck I, et al. Eplerenone is safe and effective as add-on therapy in hypertensive patients uncontrolled with calcium channel blockers or beta blockers. Eur Heart J 2002;23: 211A.
64. Wachtell K, Dahlof B, Rokkedal J, et al. Change of left ventricular geometric pattern after 1 year of anti-hypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002;144:1057-1064.
65. Ward MR, Kanellakis P, Funder J, Ramsey D, Bobik A. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-472.
66. Weber MA. Clinical implications of aldosterone blockade. Am Heart J 2002;144:S12-S18.
67. Weber M, Burgess E, Saunders E, et al. Comparative dose-response and safety of eplerenone, enalapril, losartan, and amlodipine in patients with essential hypertension. Am J Hypertens 2003;16:132A.
68. Weinberger MH, MacDonald T, Conlin PR, et al. Comparison of eplerenone and losartan in patients with low-renin hypertension. Am J Hypertens 2002;15:24A.
69. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-716.
70. Weinberger M, White W, Weiss RJ, et al. Blood pressure response to eplerenone according to baseline characteristics. Am J Hypertens 2003;16:218A.
71. Weir MR. Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med 1991; 90(Suppl 5A):3S-14S.
72. Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. Am J Cardiol 1988; 61:46H-52H.
73. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003;92:38-42.
74. White WB, Duprez D, St Hillaire R, et al. Effect of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026.
75. White WB, Menard J, Fillastre JP, et al. The selective aldosterone blocker eplerenone is more effective than losartan in patients with low-renin hypertension. Am J Hypertens 2002;15:23A.
76. White WB, Oigman W, Mion D, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinic BP in 400 patients with systemic hypertension: Results from a pivotal multinational trial. Am J Hypertens 2002;15:118A.
77. Willenbrock R, Pitt B, Darius H, et al. Selective aldosterone blockade with eplerenone regresses ventricular mass in patients with left ventricular hypertrophy. Eur Heart J 2002;23:211A-212A.
78. Willenbrock R, van Mieghem W, von Behren V, et al. Addition of eplerenone to calcium channel blockers and beta blockers improves blood pressure control. Am J Hypertens 2003;16:133A-134A.
79. Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: Effects of 11β -hydroxysteroid dehydrogenase inactivation. Endocrinology 2003;144: 1121-1125.
80. Zhang JY, Fast DM, Breau AP. Development and validation of a liquid chromatography-tandem mass spectrometric assay for eplerenone and its hydrolyzed metabolite in human plasma. J Chromatogr 2003;787: 333-344.